LabCorp Announces the Launch of the Epi proColon® Test for Colorectal Cancer Screening

First FDA-Approved Blood-Based Colorectal Cancer Test Offers Alternative for Patients Non-Compliant with Existing Screening Options BURLINGTON, N.C. --(BUSINESS WIRE)--May 9, 2016-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH) today announced the launch of Epi proColon ® , a

LabCorp to Webcast Its Annual Meeting of Stockholders

BURLINGTON, N.C. --(BUSINESS WIRE)--May 6, 2016-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH) today announced that its Annual Meeting of Stockholders will be webcast live beginning May 11, 2016 at 9:00 a.m. Eastern Daylight Time via the Company website at www.labcorp.com .

Laboratory Corporation of America® Holdings Announces 2016 First Quarter Results and Raises 2016 Guidance

Q1 Net revenue of $2.3 billion , up 30% over last year Q1 Diluted EPS of $1.55 ; Q1 Adjusted EPS of $2.02 , up 15% over last year 2016 Adjusted EPS guidance raised to $8.55 – $8.95 , up 8% to 13% over 2015 BURLINGTON, N.C. --(BUSINESS WIRE)--Apr. 25, 2016-- Laboratory Corporation of America ®

LabCorp Hires Jonathan Zung as Group President of Clinical Development and Commercialization Services for Covance Drug Development

BURLINGTON, N.C. --(BUSINESS WIRE)--Apr. 11, 2016-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE:LH) today announced that Jonathan Zung , Ph.D., has been named group president, Clinical Development & Commercialization Services for Covance Drug Development, effective April 5,

Conversion Right Triggered for Labcorp’s Zero Coupon Convertible Subordinated Notes Due 2021

BURLINGTON, N.C. --(BUSINESS WIRE)--Apr. 4, 2016-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH) announced today that its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) may be converted as set forth below.

LabCorp Completes Acquisition of Assets of Pathology, Inc.

BURLINGTON, N.C. --(BUSINESS WIRE)--Mar. 21, 2016-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH) has completed the previously-announced acquisition of substantially all of the operating assets of Pathology, Inc. following the satisfaction of all closing conditions.

Covance Announces Mobile Health Solutions to Support Use of Mobile Technology in Clinical Trials

Regulatory Consulting and Validation Services Enable Drug Development Innovation BURLINGTON, N.C. --(BUSINESS WIRE)--Mar. 14, 2016-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE:LH) today announced that Covance Drug Development (Covance) has launched Mobile Health Solutions, a

LabCorp's Zero Coupon Convertible Subordinated Notes Due 2021 to Accrue Contingent Interest

BURLINGTON, N.C. --(BUSINESS WIRE)--Mar. 11, 2016-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH) announced today that for the period of March 12, 2016 to September 11, 2016 , its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) will accrue (subject to

LabCorp is Scheduled to Present at the Barclays Capital 2016 Global Healthcare Conference

BURLINGTON, N.C. --(BUSINESS WIRE)--Mar. 8, 2016-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH) today announced it will participate at the Barclays Capital 2016 Global Healthcare Conference. LabCorp’s presentation is planned for Tuesday, March 15, 2016 at 9:00 AM (ET) .

LabCorp is Scheduled to Present at the 37th Annual Raymond James Institutional Investors Conference

BURLINGTON, N.C. --(BUSINESS WIRE)--Mar. 2, 2016-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH) today announced it will participate at the 37 th Annual Raymond James Institutional Investors Conference . LabCorp’s presentation is scheduled for Wednesday, March 9, 2016 at